Vaccines,
Год журнала:
2023,
Номер
11(10), С. 1513 - 1513
Опубликована: Сен. 23, 2023
Background:
This
study
investigated
the
impact
of
vaccinated
population
profiles,
vaccine
type/interval,
and
number
doses
on
adverse
reactions
to
receiving
a
coronavirus
disease
2019
(COVID-19)
booster
vaccination.
Methods:
A
survey
was
conducted
from
January
2022
December
among
Osaka
University
Dental
Hospital
employees
who
received
their
third
or
fourth
doses.
The
included
194
third-dose
recipients
131
fourth-dose
recipients.
Comparisons
occurrence
between
third-
groups
were
analyzed
via
chi-squared
test.
relationships
each
reaction
recipient
logistic
regression
analysis.
Results:
No
significant
differences
found
in
Younger
often
developed
injection
site
reaction,
fatigue,
chills,
fever,
arthralgia,
headache,
diarrhea,
any
more
often.
Females
had
higher
frequencies
nausea
compared
males.
Recipients
without
underlying
diseases
fever
than
those
with
diseases.
Conclusions:
females
at
risk
for
COVID-19
vaccination,
while
vaccinations,
vaccination
interval,
type,
cross-vaccination
showed
no
associations.
Globalization and Health,
Год журнала:
2024,
Номер
20(1)
Опубликована: Фев. 6, 2024
Abstract
Introduction
Indonesia
has
made
progress
in
increasing
vaccine
coverage,
but
equitable
access
remains
challenging,
especially
remote
areas.
Despite
including
vaccines
the
National
Immunization
Program
(NIP),
coverage
not
met
WHO
and
UNICEF
targets,
with
childhood
immunization
decreasing
during
COVID-19
pandemic.
vaccination
also
experienced
hesitancy,
slowing
efforts
to
end
Scope
This
article
addresses
issue
of
hesitancy
its
impact
on
initiatives
amidst
utilizes
framework
analyze
previous
outbreaks
vaccine-preventable
diseases
their
underlying
causes,
ultimately
providing
recommendations
for
addressing
current
situation.
The
analysis
considers
differences
between
pre-pandemic
circumstances
present
implementation
basic
advanced
strategies.
Key
findings
conclusion
Vaccine
is
a
significant
challenge
pandemic,
public
health
campaigns
community
engagement
are
needed
promote
acceptance
uptake.
Efforts
address
trust
healthcare
systems
increase
likelihood
individuals
seeking
preventive
services.
requires
comprehensive,
culturally
sensitive
approach
that
local
contexts
realities.
Strategies
should
be
tailored
specific
cultural
societal
monitored
evaluated.
Human Vaccines & Immunotherapeutics,
Год журнала:
2023,
Номер
19(1)
Опубликована: Янв. 2, 2023
High
and
equitable
COVID-19
vaccination
coverage
is
important
for
pandemic
control
prevention
of
health
inequity.
However,
little
known
about
socioeconomic
correlates
booster
coverage.
In
this
cross-sectional
study
all
Norwegian
adults
in
the
national
program
(N
=
4,190,655),
we
use
individual-level
registry
data
to
examine
by
levels
household
income
education
primary
(≥2
doses)
(≥3
against
COVID-19.
We
stratify
analyses
age
groups
with
different
recommendations
report
relative
risk
ratios
(RR)
25
August
2022.
18-44
y
group,
individuals
highest
vs.
lowest
had
94%
79%
(adjusted
RR
(adjRR)
1.15,
95%CI
1.14-1.15)
67%
38%
(adjRR
1.55,
95%
CI
1.55-1.56),
while
81%
1.10,
1.10-1.10)
60%
43%
1.23,
1.22-1.24).
≥45
96%
92%
1.02,
1.02-1.02)
88%
80%
1.09,
1.09-1.09),
98%
82%
1.16,
1.16-1.16)
64%
1.33,
1.33-1.34).
conclusion,
document
large
inequalities
coverage,
especially
vaccination,
even
though
was
free-of-charge.
The
results
highlight
need
tailor
information
target
underserved
vaccination.
Computers in Biology and Medicine,
Год журнала:
2024,
Номер
171, С. 108163 - 108163
Опубликована: Фев. 14, 2024
SARS-CoV-2
must
bind
its
principal
receptor,
ACE2,
on
the
target
cell
to
initiate
infection.
This
interaction
is
largely
driven
by
receptor
binding
domain
(RBD)
of
viral
Spike
(S)
protein.
Accordingly,
antiviral
compounds
that
can
block
RBD/ACE2
interactions
constitute
promising
agents.
To
identify
such
molecules,
we
performed
a
virtual
screening
Selleck
FDA
approved
drugs
and
database
Natural
Products
using
multistep
computational
procedure.
An
initial
set
candidates
was
identified
from
an
ensemble
docking
process
representative
structures
determined
analysis
four
3
μ
s
molecular
dynamics
trajectories
complex.
Two
procedures
were
used
construct
including
standard
pharmacophore
guided
The
subsequently
subjected
sieving
reduce
number
be
tested
experimentally,
increasingly
demanding
procedures,
calculation
free
energy
computed
MMPBSA
MMGBSA
methods.
After
process,
final
list
10
proposed,
which
purchased
ex-vivo.
results
estradiol
cypionate
telmisartan
as
inhibitors
entry
into
cells.
Our
findings
demonstrate
methodology
presented
here
enables
discovery
targeting
viruses
for
high-resolution
are
available.
Revista Española de Quimioterapia,
Год журнала:
2023,
Номер
36(5), С. 507 - 515
Опубликована: Июнь 12, 2023
Objectives.
Vaccination
against
SARS-CoV-2
is
essential
to
mitigate
the
personal,
social
and
global
impact
of
coronavirus
disease
(COVID-19)
as
we
move
from
a
pandemic
an
endemic
phase.
Vaccines
are
now
required
that
offer
broad,
long-lasting
immunological
protection
infection
in
addition
severe
illness
hospitalisation.
Here
present
review
evidence
base
for
new
COVID-19
vaccine,
PHH-1V
(Bimervax®;
HIPRA
HUMAN
HEALTH
S.L.U),
results
expert
consensus.
Materials
methods.
The
committee
consisted
Spanish
experts
medicine,
family
paediatrics,
immunology,
microbiology,
nursing,
veterinary
medicine.
Consensus
was
achieved
using
4-phase
process
consisting
face-to-face
meeting
during
which
scientific
reviewed,
online
questionnaire
elicit
opinions
on
value
PHH-1V,
second
update
discuss
evolution
epidemiological
situation,
vaccine
programmes
final
at
consensus
achieved.
Results.
agreed
constitutes
valuable
novel
development
vaccination
aimed
towards
protecting
population
disease.
based
broad-spectrum
efficacy
established
emerging
variants,
potent
response,
good
safety
profile.
physicochemical
properties
formulation
facilitate
handling
storage
appropriate
uptake.
Conclusions.
properties,
formulation,
immunogenicity
low
reactogenic
profile
confirm
appropriateness
this
vaccine.
PLoS ONE,
Год журнала:
2025,
Номер
20(1), С. e0309431 - e0309431
Опубликована: Янв. 3, 2025
Introduction
Vaccination
is
an
important
way
to
prevent
disease,
but
vaccine
hesitancy
will
impact
coverage
and
indirectly
affect
health.
This
study
aims
survey
the
status
of
among
adults
in
Jinan.
Methods
A
cross-sectional
was
conducted
using
scale
parents
children
teenagers
at
hospitals
Jinan,
China.
We
described
attitude
vaccination
through
dimensions
confidence
(items:
L1-L7)
risk
(items:L8-L10).The
participants
be
regarded
as
lacking
if
score
over
21
items
(L1-L7),
consider
a
“Risk”
9
(L8-L10).
Using
chi-square
test
analyse
differences
between
different
participants.
Results
202
individuals
were
enrolled,
most
respondents
(88.70%)
agreed
that
vaccines
are
for
their
child’s
33.50%
strongly
new
carried
more
risks
than
older
vaccines.
The
average
lack
11±0.25.
9.92±0.04.
Participants
aged
below
30
years,
females,
those
with
lower
education,
without
medical
workers
family
concerned
about
Conclusions
confident
vaccination.
But
they
also
knowledge
may
led
have
vaccinations.
Frontiers in Medicine,
Год журнала:
2025,
Номер
12
Опубликована: Янв. 22, 2025
Introduction
Baricitinib
is
a
selective
inhibitor
of
Janus
kinase
(JAK)1
and
JAK2,
which
associated
with
clinical
improvement
in
non-severe
COVID-19
patients.
But
severe
patients,
the
effectiveness
baricitinib
still
controversial.
Methods
A
propensity
score-matched
retrospective
study
was
conducted
to
evaluate
patients
requiring
invasive
mechanical
ventilation
(IMV).
Results
total
number
48
treated
were
included,
assigned
control
group
by
score
matching.
The
mean
ages
high
both
(baricitinib
vs.
group:
78.80
±
9.04
82.57
9.27),
most
unvaccinated
(62.5%
66.7%.
had
higher
proportion
hypertension
(73.9%
45.5%,
p
=
0.006).
Control
level
creatine
kinase-myocardial
band
(247.50
104.50,
0.021).
Patients
more
likely
receive
nirmatrelvir/ritonavir
(39.6%
16.7%,
0.017)
intravenous
immunoglobin
(14.6%
0,
0.007).
significantly
lower
all-cause
28-days
mortality
than
(72.9%
89.6%,
0.004).
Conclusion
present
revealed
reduced
on
IMV.
treating
IMV
needs
be
further
investigated
through
future
studies.
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Фев. 20, 2025
The
aims
of
this
cross-sectional
study
were
to
understand
the
healthcare
workers'
(HCWs)
practices
and
difficulties
in
communicating
with
patients
about
COVID-19
vaccinations,
investigate
factors
associated,
identify
targets
improve
efficacy
immunization
strategy.
Questionnaires
administered
between
November
2021
March
2022
three
centers
Italy.
More
than
half
HCWs
(56.8%)
reported
always
recommend
vaccination
their
patients,
recommendations
for
other
vaccinations
provided
by
50.4%
participants.
Physicians/medical
residents,
males,
those
who
recommended
more
likely
vaccination.
participants'
perception
impact
sources
information
on
patients'
knowledge
vaccination,
explored
using
a
ten-point
Likert-type
scale,
resulted
mean
value
6.3
7.9,
respectively.
A
higher
level
regarding
was
be
found
among
nurses/midwives
younger
HCWs.
It
is
important
reduce
HCWs'
perceived
gap
supporting
them
through
health
policy
engaging
increasing
uptake
rates.
Vaccines,
Год журнала:
2025,
Номер
13(4), С. 424 - 424
Опубликована: Апрель 17, 2025
Vaccination
has
been
instrumental
in
curbing
the
transmission
of
SARS-CoV-2
and
mitigating
severity
clinical
manifestations
associated
with
COVID-19.
Numerous
COVID-19
vaccines
have
developed
to
this
effect,
including
BioNTech-Pfizer
Moderna’s
mRNA
vaccines,
as
well
adenovirus
vector-based
such
Oxford–AstraZeneca.
However,
emergence
new
variants
subvariants
SARS-CoV-2,
characterized
by
enhanced
transmissibility
immune
evasion,
poses
significant
challenges
efficacy
current
vaccination
strategies.
In
review,
we
aim
comprehensively
outline
landscape
emerging
concern
(VOCs)
sub-lineages
that
recently
surfaced
post-pandemic
years.
We
assess
effectiveness
existing
their
booster
doses,
against
these
subvariants,
BA.2-derived
sub-lineages,
XBB
BA.2.86
(Pirola).
Furthermore,
discuss
latest
advancements
vaccine
technology,
multivalent
pan-coronavirus
approaches,
along
development
several
next-generation
coronavirus
exosome-based,
virus-like
particle
(VLP),
mucosal,
nanomaterial-based
vaccines.
Finally,
highlight
key
critical
areas
for
future
research
address
evolving
threat
develop
strategies
combating
viral
threats,
thereby
improving
preparedness
pandemics.